1572509-44-4

Basic information

• Product Name: N-(4-fluorophenyl)-3-[(3-methyloxetan-3-yl)sulfamoyl]benzamide
• CAS NO: 1572509-44-4
• Molecular Weight: 364.397
• Mol File: 1572509-44-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-fluorophenyl)-3-[(3-methyloxetan-3-yl)sulfamoyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-fluorophenyl)-3-[(3-methyloxetan-3-yl)sulfamoyl]benzamide(1572509-44-4)
• EPA Substance Registry System: N-(4-fluorophenyl)-3-[(3-methyloxetan-3-yl)sulfamoyl]benzamide(1572509-44-4)

Safety Data

• Hazardous Substances Data: 1572509-44-4(Hazardous Substances Data)

Upstream product

• 4052-92-0 3-chlorosulfonylbenzoyl dichloride 
• 874473-14-0 3-methyloxetane-3-amine 
• 1572516-41-6 3-(4-fluorophenylcarbamoyl)benzene-1-sulfonyl chloride 
• 371-40-4 4-fluoroaniline 

Relevant articles and documents

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)

Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.